OTCMKTS:VASO

Vaso Competitors

$0.12
-0.01 (-5.35 %)
(As of 04/9/2021 08:27 PM ET)
Add
Compare
Today's Range
$0.12
Now: $0.12
$0.12
50-Day Range
$0.09
MA: $0.10
$0.13
52-Week Range
$0.01
Now: $0.12
$0.18
Volume34,800 shs
Average Volume327,694 shs
Market Capitalization$21.30 million
P/E Ratio5.75
Dividend YieldN/A
Beta3.26

Competitors

Vaso (OTCMKTS:VASO) Vs. HSDT, FCRE, VIVE, CHFS, RSLS, and PEYE

Should you be buying VASO stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Vaso, including Helius Medical Technologies (HSDT), Fc Global Realty (FCRE), Viveve Medical (VIVE), CHF Solutions (CHFS), ReShape Lifesciences (RSLS), and Precision Optics (PEYE).

Vaso (OTCMKTS:VASO) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Vaso and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaso3.01%46.49%4.60%
Helius Medical Technologies-2,716.85%-328.07%-201.87%

Analyst Ratings

This is a summary of recent recommendations for Vaso and Helius Medical Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaso0000N/A
Helius Medical Technologies01202.67

Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 11.98%. Given Helius Medical Technologies' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Vaso.

Valuation & Earnings

This table compares Vaso and Helius Medical Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaso$75.75 million0.28$40,000.00N/AN/A
Helius Medical Technologies$1.50 million27.52$-9,780,000.00($12.94)-1.38

Vaso has higher revenue and earnings than Helius Medical Technologies.

Volatility & Risk

Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Vaso beats Helius Medical Technologies on 7 of the 10 factors compared between the two stocks.

Fc Global Realty (OTCMKTS:FCRE) and Vaso (OTCMKTS:VASO) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Fc Global Realty and Vaso's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fc Global Realty-4,265.28%-24.94%-9.42%
Vaso3.01%46.49%4.60%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Fc Global Realty and Vaso, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fc Global Realty0000N/A
Vaso0000N/A

Valuation and Earnings

This table compares Fc Global Realty and Vaso's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fc Global Realty$40,000.00971.79$-2,040,000.00N/AN/A
Vaso$75.75 million0.28$40,000.00N/AN/A

Vaso has higher revenue and earnings than Fc Global Realty.

Volatility and Risk

Fc Global Realty has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500.

Summary

Vaso beats Fc Global Realty on 6 of the 7 factors compared between the two stocks.

Vaso (OTCMKTS:VASO) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares Vaso and Viveve Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaso$75.75 million0.28$40,000.00N/AN/A
Viveve Medical$6.57 million5.12$-42,530,000.00($338.00)-0.01

Vaso has higher revenue and earnings than Viveve Medical.

Profitability

This table compares Vaso and Viveve Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaso3.01%46.49%4.60%
Viveve Medical-661.57%-243.62%-139.23%

Institutional and Insider Ownership

18.2% of Viveve Medical shares are owned by institutional investors. 44.0% of Vaso shares are owned by company insiders. Comparatively, 5.0% of Viveve Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vaso and Viveve Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaso0000N/A
Viveve Medical00103.00

Volatility & Risk

Vaso has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Summary

Vaso beats Viveve Medical on 8 of the 11 factors compared between the two stocks.

Vaso (OTCMKTS:VASO) and CHF Solutions (NASDAQ:CHFS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Vaso and CHF Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaso3.01%46.49%4.60%
CHF Solutions-254.26%-173.61%-131.01%

Analyst Recommendations

This is a summary of recent ratings and price targets for Vaso and CHF Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaso0000N/A
CHF Solutions00103.00

CHF Solutions has a consensus target price of $20.00, suggesting a potential upside of 270.37%. Given CHF Solutions' higher probable upside, analysts plainly believe CHF Solutions is more favorable than Vaso.

Valuation and Earnings

This table compares Vaso and CHF Solutions' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaso$75.75 million0.28$40,000.00N/AN/A
CHF Solutions$5.51 million5.92$-18,110,000.00($279.28)-0.02

Vaso has higher revenue and earnings than CHF Solutions.

Institutional & Insider Ownership

65.1% of CHF Solutions shares are owned by institutional investors. 44.0% of Vaso shares are owned by company insiders. Comparatively, 0.6% of CHF Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, CHF Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Summary

Vaso beats CHF Solutions on 8 of the 12 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLS) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for ReShape Lifesciences and Vaso, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences00103.00
Vaso0000N/A

Profitability

This table compares ReShape Lifesciences and Vaso's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-314.18%-186.31%-101.10%
Vaso3.01%46.49%4.60%

Volatility and Risk

ReShape Lifesciences has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Vaso has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500.

Valuation and Earnings

This table compares ReShape Lifesciences and Vaso's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$15.09 million1.70$-74,210,000.00N/AN/A
Vaso$75.75 million0.28$40,000.00N/AN/A

Vaso has higher revenue and earnings than ReShape Lifesciences.

Summary

Vaso beats ReShape Lifesciences on 6 of the 8 factors compared between the two stocks.

Vaso (OTCMKTS:VASO) and Precision Optics (OTCMKTS:PEYE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Vaso and Precision Optics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaso0000N/A
Precision Optics0000N/A

Profitability

This table compares Vaso and Precision Optics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaso3.01%46.49%4.60%
Precision Optics-13.17%-46.31%-22.21%

Valuation and Earnings

This table compares Vaso and Precision Optics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaso$75.75 million0.28$40,000.00N/AN/A
Precision Optics$9.92 million2.25$-1,430,000.00N/AN/A

Vaso has higher revenue and earnings than Precision Optics.

Risk and Volatility

Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Summary

Vaso beats Precision Optics on 7 of the 8 factors compared between the two stocks.


Vaso Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.86-3.3%$41.27 million$1.50 million-1.02
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.25-5.2%$33.61 million$6.57 million-0.01
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.40-1.9%$32.60 million$5.51 million-0.11
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.15-0.7%$25.59 million$15.09 million0.00
PEYE
Precision Optics
0.4$1.69-5.0%$22.35 million$9.92 million-16.85Gap Down
STRR
Star Equity
0.1$3.30-2.7%$16.24 million$114.18 million-1.05
GTHP
Guided Therapeutics
0.3$0.75-4.6%$10.41 million$40,000.00-3.13Gap Up
Micron Solutions logo
MICR
Micron Solutions
0.3$3.00-3.0%$10.09 million$17.50 million21.43Gap Down
NIMU
Non-Invasive Monitoring Systems
0.5$0.03-11.8%$2.69 millionN/A0.00Gap Up
RSLSD
ReShape Lifesciences
0.4$5.37-2.2%$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.17-41.0%$1.20 millionN/A6.50Gap Up
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55-29.1%$1.12 millionN/A0.00Gap Down
ARDMQ
Aradigm
0.0$0.05-8.7%$764,000.00N/A0.00Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03-1.9%$359,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01-0.0%$312,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$265,000.00N/A0.00
ULGX
Urologix
0.6$0.01-43.3%$192,000.00N/A0.00Gap Down
AKSY
Aksys
0.0$0.00-40.0%$0.00N/A0.00Gap Down
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.35-5.7%$0.00$9.40 million-5.83Gap Down
HRTT
Heart Tronics
0.0$0.15-466.7%$0.00N/A0.00Gap Up
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-14.7%$0.00N/A0.00Gap Up
PECN
Photoelectron
0.2$0.03-3.8%$0.00N/A0.00Gap Up
Trimedyne logo
TMED
Trimedyne
0.4$4.25-0.2%$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.